Home Newsfeeds SVB Leerink Reiterates Outperform on Elevance Health, Maintains $580 Price Target

SVB Leerink Reiterates Outperform on Elevance Health, Maintains $580 Price Target

SVB Leerink analyst Whit Mayo reiterates Elevance Health (NYSE:ELV) with a Outperform and maintains $580 price target.

byBenzinga Newsdesk

January 26, 2023

1 minute read

SVB Leerink analyst Whit Mayo reiterates Elevance Health (NYSE:ELV) with a Outperform and maintains $580 price target.

BMO Capital Maintains Outperform on CrowdStrike Holdings, Raises Price Target to $152

By Benzinga Newsdesk

March 8, 7:27 AM

BMO Capital analyst Keith Bachman maintains CrowdStrike Holdings (NASDAQ:CRWD) with a Outperform and raises the price target from $120 to $152.

CRWD

$100 Invested In ResMed 10 Years Ago Would Be Worth This Much Today

By Benzinga Insights

February 8, 12:34 PM

ResMed (NYSE:RMD) has outperformed the market over the past 10 years by 7.12% on an annualized basis producing…

RMD

Raoul Pal Spills Secrets: How To ‘Make Life-Changing Money’ In Crypto Within 2 Years

By Murtuza Merchant

January 18, 12:23 PM

Macro investor Raoul Pal is predicting "life-changing wealth creation" in the crypto space over the next few years.

BTC

Enhabit Urges Stockholders to Vote for Current Board, Opposes AREX Capital’s Bid for Control

By Benzinga Newsdesk

June 10, 7:49 AM

Enhabit, Inc. (NYSE:EHAB) ("Enhabit" or the "Company"), a leading home health and hospice provider, today announced that it has filed definitive proxy materials with the Securities and Exchange

EHAB

SVB Leerink Reiterates Outperform on Elevance Health, Maintains $580 Price Target

Related Posts

BMO Capital Maintains Outperform on CrowdStrike Holdings, Raises Price Target to $152

$100 Invested In ResMed 10 Years Ago Would Be Worth This Much Today

Raoul Pal Spills Secrets: How To ‘Make Life-Changing Money’ In Crypto Within 2 Years

Enhabit Urges Stockholders to Vote for Current Board, Opposes AREX Capital’s Bid for Control